INDIGO Trial Insights: Patient Selection, Progression-Free Survival, and Tumor Control

IDH-mutant diffuse gliomas often follow a gradual but persistent course, with tumor growth and neurologic symptoms evolving over time. As treatment strategies shift toward earlier, targeted intervention, understanding how therapies perform in carefully selected patient populations has become increasingly important for guiding clinical decision-making.

At the 2026 AAN Annual Meeting in Chicago, Katherine B. Peters, MD, PhD, neuro-oncologist at Duke Health and professor of neurology and neurosurgery at the Preston Robert Tisch Brain Tumor Center, spoke with NeurologyLive® about findings from the phase 3 INDIGO trial (NCT04164901), which evaluated vorasidenib in patients with IDH-mutant diffuse glioma. The study represents one of the most notable advances in this space, particularly for patients with nonenhancing, low-grade tumors who may otherwise be monitored following surgery. Peters discussed how the trial design, including its placebo-controlled approach and crossover component, offers important insight into disease trajectory and treatment timing, while also helping to contextualize outcomes beyond traditional endpoints such as progression-free survival.

In this episode, Peters provides an overview of the INDIGO trial design, including its focus on patients with measurable, nonenhancing, and actively growing tumors. She highlights the trial’s significant progression-free survival benefit, the delay in time to next intervention, and additional secondary outcomes that explored quality of life, cognition, and seizure burden.